Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated September 10, 2007, reports on a significant legal and financial event concerning the company's antiviral medicine, Famvir. The filing addresses an "at-risk" generic launch by Teva Pharmaceuticals in the United States, despite Novartis holding valid patents until 2015.
Key Financial Metrics
- Impairment Charge: A one-time accounting charge for the impairment of intangible assets is expected in the third quarter of 2007, ranging from USD 250 million to USD 300 million.
- Famvir US Sales (2006): Net sales were USD 166 million.
- Group Performance (2006): Net sales of USD 37.0 billion and net income of USD 7.2 billion.
- R&D Investment (2006): Approximately USD 5.4 billion.
Material Changes and Events
The primary material change is the initiation of a one-time impairment charge due to Teva's generic launch. This launch occurred after the US District Court in Newark, New Jersey, denied Novartis's request for a preliminary injunction on September 5, 2007. The two companies are engaged in patent infringement litigation that began in 2005. If Novartis prevails, Teva faces potentially significant damages.
Guidance, Outlook, and Risks
Novartis reaffirms its 2007 outlook despite the Famvir situation:
- Income: Record operating and net income from continuing operations.
- Sales Growth: Mid-single-digit growth in net sales for Group continuing operations and low-single-digit growth for the Pharmaceuticals Division (both in local currencies).
Risks and Contingencies: The filing highlights risks related to the ongoing patent litigation, potential regulatory actions, pricing pressures, and the uncertainty of future Famvir revenue levels. The company notes that actual results may vary materially from forward-looking statements due to these factors.
Investor Verification Checklist
- Verify the final amount of the Q3 2007 impairment charge within the stated USD 250 million to USD 300 million range.
- Monitor the status of the patent infringement litigation between Novartis and Teva Pharmaceuticals.
- Track the impact of the generic launch on Famvir's US sales performance in subsequent quarters.
- Confirm whether the company maintains its guidance for record operating and net income for the full year 2007.